Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
J Biol Chem. 2013 Jul 5;288(27):19845-60. doi: 10.1074/jbc.M113.460170. Epub 2013 May 17.
The four PDZ (PDZ1 to PDZ4) domain-containing adaptor protein PDZK1 controls the expression, localization, and function of the HDL receptor scavenger receptor class B, type I (SR-BI), in hepatocytes in vivo. This control depends on both the PDZ4 domain and the binding of SR-BI's cytoplasmic C terminus to the canonical peptide-binding sites of either the PDZ1 or PDZ3 domain (no binding to PDZ2 or PDZ4). Using transgenic mice expressing in the liver domain deletion (ΔPDZ2 or ΔPDZ3), domain replacement (PDZ2→1), or target peptide binding-negative (PDZ4(G389P)) mutants of PDZK1, we found that neither PDZ2 nor PDZ3 nor the canonical target peptide binding activity of PDZ4 were necessary for hepatic SR-BI regulatory activity. Immunohistochemical studies established that the localization of PDZK1 on hepatocyte cell surface membranes in vivo is dependent on its PDZ4 domain and the presence of SR-BI. Analytical ultracentrifugation and hydrogen deuterium exchange mass spectrometry suggested that the requirement of PDZ4 for localization and SR-BI regulation is not due to PDZ4-mediated oligomerization or induction of conformational changes in the PDZ123 portion of PDZK1. However, surface plasmon resonance analysis showed that PDZ4, but not the other PDZ domains, can bind vesicles that mimic the plasma membrane. Thus, PDZ4 may potentiate PDZK1's regulation of SR-BI by promoting its lipid-mediated attachment to the cytoplasmic membrane. Our results show that not all of the PDZ domains of a multi-PDZ domain-containing adaptor protein are required for its biological activities and that both canonical target peptide binding and noncanonical (peptide binding-independent) capacities of PDZ domains may be employed by a single such adaptor for optimal in vivo activity.
PDZ 结构域 4 (PDZ1 到 PDZ4) 含有衔接蛋白 PDZK1 控制了体内肝细胞中 HDL 受体清道夫受体 B 型,I 类(SR-BI)的表达、定位和功能。这种控制既依赖于 PDZ4 结构域,又依赖于 SR-BI 的细胞质 C 末端与 PDZ1 或 PDZ3 结构域的经典肽结合位点结合(不与 PDZ2 或 PDZ4 结合)。利用在肝脏中表达的转基因小鼠进行结构域缺失(ΔPDZ2 或 ΔPDZ3)、结构域替换(PDZ2→1)或靶肽结合阴性(PDZ4(G389P))的 PDZK1 突变体的研究,我们发现 PDZ2 和 PDZ3 以及 PDZ4 的经典靶肽结合活性对肝 SR-BI 的调节活性都不是必需的。免疫组织化学研究确立了体内 PDZK1 在肝细胞细胞膜表面的定位依赖于其 PDZ4 结构域和 SR-BI 的存在。分析超速离心和氢氘交换质谱分析表明,PDZ4 对定位和 SR-BI 调节的要求不是由于 PDZ4 介导的寡聚化或 PDZK1 的 PDZ123 部分诱导构象变化所致。然而,表面等离子体共振分析表明,PDZ4 而不是其他 PDZ 结构域可以结合模拟质膜的小泡。因此,PDZ4 可以通过促进其与质膜的脂质介导附着来增强 PDZK1 对 SR-BI 的调节。我们的结果表明,多 PDZ 结构域含有衔接蛋白的并非所有 PDZ 结构域都与其生物学活性有关,并且 PDZ 结构域的经典靶肽结合和非经典(与肽结合无关)能力都可能被单个此类衔接蛋白用于最佳的体内活性。